Previous 10 | Next 10 |
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Kriya Therapeutics , Inc., a fully integrated company pioneering novel technologies and therapeutics in...
The following slide deck was published by Twist Bioscience Corporation in conjunction with this event. For further details see: Twist Bioscience Corp (TWST) Investor Presentation - Slideshow
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced it has become a part of the Digital Preservation Coalition’s (DPC) Supporter Program, where memb...
The following slide deck was published by Twist Bioscience Corporation in conjunction with their 2022 Q1 earnings call. For further details see: Twist Bioscience Corporation 2022 Q1 - Results - Earnings Call Presentation
Twist Bioscience (NASDAQ:TWST) has priced an upsized, underwritten public offering of 4,545,454 shares of its common stock at a price to the public of $55.00/share for an expected gross proceeds of ~$250M. Underwriters are granted a 30-day option to purchase up to an additional 681,818 shares...
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the pricing of an upsized, underwritten public offering of 4,545,454 shares of its common stock at a price ...
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Jim Thorburn, CFO of Twist Biosc...
Twist Bioscience (NASDAQ:TWST) announced a proposed $200M underwritten public offering of shares. TWST intends to grant the underwriters a 30-day option to purchase up to $30M of shares. Net proceeds, along with existing cash, will be used to scale its investment in its R&D organizat...
Twist will leverage C2i’s leadership in whole-genome cancer signatures across solid cancers to generate unique synthetic reference materials for cancer detection validation in labs across the globe C2i to integrate Twist’s library preparation kits into minimal re...
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Eleven Therapeutics, a company leading the AI revolution in nucleic acid therapies, today announced that they have ...
News, Short Squeeze, Breakout and More Instantly...
Twist Bioscience Corporation Company Name:
TWST Stock Symbol:
NASDAQ Market:
Twist Bioscience Corporation Website:
Pure Biologics’ exploratory Phase 0 study to evaluate pharmacodynamic activity of PBA-0405 in solid tumors Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today a...
Company to host conference call at 8:00 AM ET Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2024 th...
Express Genes enable faster turnaround times Twist Express Antibodies, CHO starting at 13 business days Twist Express Antibodies, HEK293 starting at 10 business days Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of ...